ZBH vs BIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 21, 2026

ZBH

39.4
AI Score
VS
BIO Wins

BIO

70.1
AI Score

Investment Advisor Scores

ZBH

39score
Recommendation
SELL

BIO

70score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ZBH BIO Winner
Revenue 4.26B 1.24B ZBH
Net Income 436.50M -155.70M ZBH
Net Margin 10.2% -12.5% ZBH
Operating Income 699.20M 106.70M ZBH
ROE 3.5% -2.2% ZBH
ROA 1.9% -1.5% ZBH
Total Assets 22.80B 10.25B ZBH
Cash 410.00M 517.00M BIO
Debt/Equity 0.50 0.17 BIO
Current Ratio 1.69 3.14 BIO
Free Cash Flow 716.70M 144.80M ZBH

Relative Price Performance (Last 90 Days)

ZBH 1M: +0.9% · 3M: +5.8% BIO 1M: -5.0% · 3M: +13.9%

Current Technical Phase

ZBH

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 56

RSI (14): 55.8 · Price: $94.86

BIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 45.8 · Price: $360.50

Fundamentals Snapshot

Metric ZBH BIO
Market Cap — —
Forward P/E 10.5 37.0
Trailing P/E 23.3 44.9
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin 0.7% 0.5%
Operating Margin 0.2% 0.1%
EPS 4.12 7.89
Dividend Yield 0.01% —

Frequently Asked Questions

Based on our detailed analysis, BIO is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.